


Accelerating
Precision Oncology
From translational research to clinical development to commercialization, we meet your needs at every stage of drug development.
Precision Medicine is Driving a New Era in Oncology Drug Development
Biopharma companies are at the forefront of introducing novel targeted therapies, redefining the therapeutic management of cancer. These treatments target the specific alterations or biomarkers of a patient, which can significantly extend progression-free survival compared with traditional chemotherapy or immunotherapy.1-4

Add a New Dimension of Insights
to Your View of Cancer
Power Your Next Breakthrough With Guardant Infinity™
Guardant Infinity is the first and only commercially available platform that combines genomic and epigenomic profiling using our proprietary nondestructive methylation technology—enabling access to epigenomic insights that are scalable from research to the clinic.11
Epigenomics examines chemical and structural modifications to DNA and histones that can affect gene expression and the regulation of biological processes that drive cancer.11,12
Expand Patient Eligibility for Targeted Therapies
Guardant Infinity can detect promoter methylation and methylation signatures to identify more patients, including those missed by a genomic-only approach.11,13,14
Studies have shown that novel epigenomic biomarkers can reveal:
Adverse Event Prediction15-17
Response Prediction15-17
Tumor
Subtyping18
Tumor of
Origin19